Search

Displaying results 1471 - 1480 of 4692 in total
  1. Drug

    Bremelanotide

    go.drugbank.com/drugs/DB11653
    Approved

    [A179683] Since then it was investigated for its place in treating sexual dysfunction in men and women but is now only indicated for women. … [A179686] The mechanism by which bremelanotide's action on receptors translates to a clinical effect is still unknown.

  2. Drug

    Acalabrutinib

    go.drugbank.com/drugs/DB11703
    ApprovedInvestigational

    To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administer...

  3. Drug

    Dantrolene

    go.drugbank.com/drugs/DB01219
    ApprovedInvestigational

    Chemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin.

  4. Target

    Transcription factor Jun

    go.drugbank.com/bio_entities/BE0001040
    TargetHumans

    Heterodimerizes with proteins of the FOS family to form an AP-1 transcription complex, thereby enhancing its DNA binding activity to the AP-1 consensus sequence 5'-TGA[GC]TCA-3' and enhancing its transcriptional

    Synonyms: V-jun avian sarcoma virus 17 oncogene homolog
  5. Drug

    Tislelizumab

    go.drugbank.com/drugs/DB14922
    ApprovedInvestigational

    [L49439] Tislelizumab was also approved by the FDA on March 14, 2024.[L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349] … [A262909] By blocking PD-L1/PD-L2–mediated cell signaling, tislelizumab restores T-cell function through cytokine production, resulting in immune-mediated antitumor responses.

  6. Drug

    Orforglipron

    go.drugbank.com/drugs/DB18964
    ApprovedInvestigational

    [L56123] On April 1, 2026, the US FDA granted approval to orforglipron for use alongside diet and exercise to aid in weight reduction in certain patient populations.

  7. Drug

    Agmatine

    go.drugbank.com/drugs/DB08838
    Experimental

    Up to now (July 2013), the results of this study have not yet been published. … It is formed when arginine is decarboxylated by the enzyme arginine decarboxylase and is found naturally in ragweed pollen, ergot fungi, octopus muscle, herring sperm, sponges, and the mammalian brain.

  8. Drug

    scAAV9.U7.ACCA

    go.drugbank.com/drugs/DB18582
    Investigational

    Developed by Nationwide Children’s Hospital, it is being investigated for the treatment of Duchenne muscular dystrophy. … scAAV9.U7.ACCA is a non-replicating recombinant adeno-associated virus vector containing 4 antisense sequences designed to target exon 2 in the human DMD gene under the control of U7 small nuclear non-coding

    Synonyms: scAAV9.U7.ACCA, non-replicating recombinant adeno-associated virus vector containing 4 antisense sequences designed to target exon 2 in the human DMD gene under the control of U7 small nuclear non-coding RNA
  9. Target

    Human Vascular Endothelial Growth Factors (VEGFs)

    go.drugbank.com/bio_entities/BE0010103
    TargetHumans

    Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A (PubMed:35455969). Involved in protecting cells from hypoxia-mediated cell death (By similarity)

    Polypeptides: Vascular endothelial growth factor A, long form
  10. Drug

    Penpulimab

    go.drugbank.com/drugs/DB16747
    ApprovedInvestigational

    [A273843,A273848] Penpulimab-kcqx was approved by the US FDA in April 2025 for the treatment of nasopharyngeal carcinoma in select patients.[L52993,L52998]